Questionable oncologic benefits of degarelix.

•The studies supporting the use of degarelix are methodologically flawed.•Studies populations are heterogeneous, with ad hoc analyses & low statistical merit.•Selected data is presented that would appear to be favorable to degarelix.•None of the data that they point out have any association with clinical benefit.•The evidence to support the use of degarelix is rather weak.